On April 11th, Chen Fener, Academician of the Chinese Academy of Engineering and President of Jiangxi Normal University, Xiang Guoxiong, Vice President of Jiangxi Normal University, and Zhou Jianguo, Director of the Party Committee (President's Office), visited Fushine Pharmaceuticals to discuss further university-enterprise collaboration, industry-university-research development, and talent development. Fushine Pharmaceuticals Chairman and General Manager Bao Jianhua, Vice Chairman and Chief Engineer Li Huiyue, and Deputy General Manager and General Manager of Xiangtai Science Liu Ying were also in attendance.

Academician Chen from Jiangxi Normal University and his delegation took a group photo with the chairman of Fushine Pharmaceuticals and other company representatives

At the beginning of the meeting, Chairman Bao Jianhua warmly welcomed the arrival of Academician Chen Fener and his delegation, and Deputy General Manager Liu Ying gave a detailed introduction to the company's basic situation, future development strategy and Xiangtai Science's specific business.

Academician Chen Fener is an academician of the Chinese Academy of Engineering and president of Jiangxi Normal University. She has been engaged in synthetic medicinal chemistry and pharmaceutical engineering research for a long time and has made extraordinary achievements in pharmaceutical manufacturing, fine organic chemicals and engineering. As the first finisher, she won one second prize in the National Invention Award, one second prize in the National Science and Technology Progress Award, three first prizes in provincial and ministerial science and technology progress awards, and one China Patent Gold Award. She has also applied for and been authorized for many invention patents.

Academician Chen Fener pointed out that new processes such as continuous production have enormous potential in the field of pharmaceutical production. They can greatly improve production processes and enhance product quality while meeting the personalized development needs of enterprises. He also shared recent research results on new processes in the pharmaceutical field. He also stated that Fushine Pharmaceuticals has been continuously cultivating the pharmaceutical sub-sector for more than 20 years, actively expanding upstream and downstream of the product supply chain around the pharmaceutical business. It has accumulated profound experience in commercial production, quality management, and EHS management in the pharmaceutical field, and has advantages in chemical process technology and engineering equipment technology. Jiangxi Normal University is willing to work with Fushine Pharmaceuticals to cultivate professional talents, establish a joint laboratory, and carry out industry-university-research collaboration. Together, they will commit to technological innovation in the pharmaceutical field and promote fruitful results in the development of pharmaceutical raw materials and the application of new processes.

Bao Jianhua stated that Jiangxi Normal University, as a participant in the "Basic Capacity Building Project for Colleges and Universities in Central and Western China," is one of the first national demonstration institutions for deepening innovation and entrepreneurship education reform. With a long history and a strong faculty, Jiangxi Normal University boasts a strong professional background and distinctive advantages in scientific research innovation, talent development, and strategic emerging industries. It boasts a large number of highly qualified professionals capable of providing intellectual support for economic and social development, significantly impacting Jiangxi's social development. The new pharmaceutical technology mentioned by Academician Chen Fener is highly aligned with Fushine Pharmaceuticals' pharmaceutical business segment. Fushine Pharmaceuticals is committed to working with Jiangxi Normal University to advance China's pharmaceutical industry and contribute positively to the province's industrial and economic development.
Following the meeting, the two sides reached a preliminary agreement on cooperation regarding school-enterprise collaboration and talent team building. Subsequently, the two sides will further deepen exchanges and explore the possibility of jointly building a scientific research team between the school and the enterprise, thus opening a new chapter in talent transfer, research achievement transformation, and industry-research integration.